menu
    • menu
    [{"orgOrder":0,"company":"AP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AP402","moa":"p95HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AP402","moa":"p95HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"AP203","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AP505","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AP601","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AP Biosciences \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"AP Biosciences \/ Avance Clinical"}]

    Find Clinical Drug Pipeline Developments & Deals by AP Biosciences

    Menu

    AP Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP601

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors

                            Details : AP601 is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 10, 2025

                            Lead Product(s) : AP601

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP402

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AP Biosciences Doses First HER2+ Cancer Patient in AP402 Trial

                            Details : AP402, a potential first-in-class, next generation T cell engager targeting CD137 and p95HER2 in patients relapsed/refractory to anti-HER2 treatment.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : AP402

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP505

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors

                            Details : AP505 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : AP505

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP402

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

                            Details : AP402 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 01, 2024

                            Lead Product(s) : AP402

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            AP Biosciences

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP203

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally A...

                            Details : AP203 is a Dietary Supplement drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            July 25, 2022

                            Lead Product(s) : AP203

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth